| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 05/02/2002 | EP1200462A2 Use of quinic, shikimic acids and their derivatives for preparing mannose receptor ligands |
| 05/02/2002 | EP1200460A1 Pseudomycin n-acyl side-chain analogs |
| 05/02/2002 | EP1200458A1 Uses of peptides derived from the cytoplasmic domain of the amyloid protein precursor (app) |
| 05/02/2002 | EP1200457A2 Cysteine protease inhibitors |
| 05/02/2002 | EP1200456A1 Antisense modulation of pten expression |
| 05/02/2002 | EP1200440A1 Quinuclidine derivatives for treatment of neurological disorders |
| 05/02/2002 | EP1200317A1 A device for spray dispensing a composition for topical application comprising vitamin e and essential fatty acids |
| 05/02/2002 | EP1200140A1 Controlled release implantable devices |
| 05/02/2002 | EP1200137A1 Agent for occluding blood vessels |
| 05/02/2002 | EP1200133A1 Manipulation of tissue or organ type using the notch pathway |
| 05/02/2002 | EP1200127A2 Solutions and methods for inhibition of pain, inflammation and cartilage degradation |
| 05/02/2002 | EP1200125A1 Psca: prostate stem cell antigen and uses thereof |
| 05/02/2002 | EP1200124A1 Immunoglobulin fusion proteins |
| 05/02/2002 | EP1200123A1 Diagnosis and treatment of neuroectodermal tumors |
| 05/02/2002 | EP1200119A2 Method for down-regulating gdf-8 activity |
| 05/02/2002 | EP1200118A1 A pharmaceutical formulation comprising a low molecular weight thrombin inhibitor and its prodrug |
| 05/02/2002 | EP1200117A2 Lipoprotein lipase (lpl) variant therapeutics |
| 05/02/2002 | EP1200116A2 USE OF FVIIa OR A TISSUE FACTOR ANTAGONIST FOR REGULATING GENE EXPRESSION AND CELL MIGRATION OR CHEMOTAXIS |
| 05/02/2002 | EP1200115A2 Multi-dose erythropoietin formulations |
| 05/02/2002 | EP1200114A2 Ppar delta inhibitors for the treatment of cardiovascular diseases |
| 05/02/2002 | EP1200113A2 Reagents and methods useful for detecting diseases of the prostate |
| 05/02/2002 | EP1200112A2 Chemokine binding protein of gammaherpesvirus 68 and methods of use therefor |
| 05/02/2002 | EP1200111A1 Compositions for the treatment of the catabolic state of prolonged critical illness |
| 05/02/2002 | EP1200109A1 Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions |
| 05/02/2002 | EP1200105A1 Modified factor viii |
| 05/02/2002 | EP1200104A1 Cadmium containing compositions |
| 05/02/2002 | EP1200101A1 Methods for transdifferentiation of body tissues |
| 05/02/2002 | EP1200078A1 Compositions and methods for promoting nerve regeneration |
| 05/02/2002 | EP1200074A2 Use of diphenyliodonium for the activation and protection of cytotoxic lymphocytes |
| 05/02/2002 | EP1200067A1 Delivery system for biological material |
| 05/02/2002 | EP1173192A4 Methods and compositions for targeted drug delivery |
| 05/02/2002 | EP0975216A4 A method for treating papillomavirus infections |
| 05/02/2002 | EP0910375B1 A composition of enalapril and losartan |
| 05/02/2002 | EP0879056B1 Modulation of th1/th2 cytokine expression by ribavirin in activated t-lymphocytes |
| 05/02/2002 | EP0859854B1 Retroviral vectors carrying senescent cell derived inhibitors 1 (sdi-1) or antisense sdi-1 nucleotide sequences |
| 05/02/2002 | EP0772442B1 Use of immunosuppressive agents for the treatment of schizophrenia |
| 05/02/2002 | EP0746567B1 Novel opioid peptides for the treatment of pain and use thereof |
| 05/02/2002 | EP0724884B1 Side effect inhibitor for cancer therapy |
| 05/02/2002 | EP0593585B1 Peptide which abrogates tnf and lps toxicity |
| 05/02/2002 | DE10053506A1 Preventing aminoglycoside-induced damage to organs, especially the kidneys or inner ear, by administration of megalin receptor antagonist, e.g. polymyxin B |
| 05/02/2002 | DE10050831A1 Verfahren zum Zyklusstart bei weiblichen Zuchttieren A method for cycle start at breeding ewes |
| 05/02/2002 | DE10049549A1 Inhibitor of the transcription factor IFR-1, useful for treating e.g. transplant rejection and autoimmune disease, reduces expression of CD40 |
| 05/02/2002 | CA2689012A1 Method for the treatment of neurological and neuropsychological disorders |
| 05/02/2002 | CA2678256A1 Methods of treating vascular diseases characterized by nitric oxide insufficiency |
| 05/02/2002 | CA2464228A1 Vaccine immunotherapy for immune suppressed patients |
| 05/02/2002 | CA2428907A1 Use of pericyte apoptosis inhibitors for treating and/or preventing diabetic retinopathy |
| 05/02/2002 | CA2427085A1 Transmembrane proteins |
| 05/02/2002 | CA2427070A1 Preferred segments of neural thread protein and methods of using the same |
| 05/02/2002 | CA2427005A1 Multi-component antioxidant compounds, pharmaceutical compositions containing same and their use for reducing or preventing oxidative stress |
| 05/02/2002 | CA2426902A1 Methods of improving central nervous system functioning |
| 05/02/2002 | CA2426779A1 Methods for identifying compounds for regulating muscle mass or function using vasoactive intestinal peptide receptors |
| 05/02/2002 | CA2426738A1 Streptococcal genes |
| 05/02/2002 | CA2426736A1 Vegf peptides and their use for inhibiting angiogenesis |
| 05/02/2002 | CA2426463A1 Novel aggrecanase molecules |
| 05/02/2002 | CA2426094A1 Amyloid precursor protein and app-derived peptides inhibit tumor growth and metastasis |
| 05/02/2002 | CA2425897A1 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof |
| 05/02/2002 | CA2425770A1 Using heat shock proteins to increase immune response |
| 05/02/2002 | CA2425596A1 Methods of therapy for hiv infection |
| 05/02/2002 | CA2424475A1 Method for the treatment of neurological and neuropsychological disorders |
| 05/02/2002 | CA2422953A1 Identification and modification of immunodominant epitopes in polypeptides |
| 05/02/2002 | CA2422787A1 C-nitroso compounds and use thereof |
| 05/02/2002 | CA2421885A1 Methods of treating vascular diseases characterized by nitric oxide insufficiency |
| 05/01/2002 | CN1347421A Antifungal agents isolated from pseudomonas syringae |
| 05/01/2002 | CN1347420A Growth hormone secretagogues |
| 05/01/2002 | CN1347419A Pyrrolidincarbonylamino cyclic disulfides |
| 05/01/2002 | CN1347327A Methods for glucagon suppression |
| 05/01/2002 | CN1347326A BAFF, inhibitors thereof and their use in modulation of B-cell response |
| 05/01/2002 | CN1347325A Novel amide derivs. as growth hormone secretagogues |
| 05/01/2002 | CN1347310A Skin care compositions contg. combination of skin care actives |
| 05/01/2002 | CN1347309A Skin care compositions contg. combination of skin care actives |
| 05/01/2002 | CN1347308A Skin care compositions contg. combination of skin care actives |
| 05/01/2002 | CN1347283A eNOS mutations useful for gene therapy and therapeutic screening |
| 05/01/2002 | CN1346888A Method for producing transgene non-human mammal |
| 05/01/2002 | CN1346831A Purified polypeptide with bioactivity and medicine prepared from it for promoting growth and development of animal's nerve cells and suppressing their apotosis |
| 05/01/2002 | CN1346676A Medicine for treating nerve injury |
| 04/30/2002 | US6380398 Compounds such as (s,s)1-(2-amino-3,3-dimethyl-butyryl)-2,5-dihydro-1h-pyrrole-2 -carbonitrile administered as antidiabetic agents; dipeptidyl peptidase-iv (dpp-iv) |
| 04/30/2002 | US6380387 Antiinflammatory agents, antiasthmatics |
| 04/30/2002 | US6380382 Isolated nucleic acid |
| 04/30/2002 | US6380376 Purity polypeptides |
| 04/30/2002 | US6380374 Isolated nucleic acid; culture product |
| 04/30/2002 | US6380371 Endoglycan: a novel protein having selectin ligand and chemokine presentation activity |
| 04/30/2002 | US6380364 Complexing; genetic engineering |
| 04/30/2002 | US6380363 Antibodies to the Ob receptor |
| 04/30/2002 | US6380362 Genetic engineering |
| 04/30/2002 | US6380360 Polycystic kidney disease 1 gene and uses thereof |
| 04/30/2002 | US6380359 Liposomes comprising peptide antigens derived from X protein of hepatitis B virus |
| 04/30/2002 | US6380357 Solution comprises purified glucagon-like peptide-1, buffering agent containing alcohol or mono/di- saccharide, and optionally ammonium sulfate; tetragonal flat rod shaped crystals formed; useful in treating diabetes and obesity |
| 04/30/2002 | US6380356 Multivalent polymyxin antibiotics |
| 04/30/2002 | US6380355 Process for obtaining insulin precursors having correctly bonded cystine bridges |
| 04/30/2002 | US6380262 5-membered ring compounds |
| 04/30/2002 | US6380255 Treatment for dermal skin atrophy using thyroid hormone compounds or thyroid hormone-like compounds |
| 04/30/2002 | US6380253 Obtaining initial radiographic image of a region containing glioma; injecting into glioma region an anti-angiogenic substance which is linked to sodium salt solution of polyunsaturated fatty acid; obtaining image; evaluation |
| 04/30/2002 | US6380215 For prevention and/or treatment of diseases caused by thrombus formation such as arterial thrombosis, arterial sclerosis, ischemic heart diseases |
| 04/30/2002 | US6380183 Treatment of diseases involving cyst formation |
| 04/30/2002 | US6380171 Administering antisense nucleic acid having a nucleotide sequence to suppress expression of pro-protein converting enzyme 5 (pc5) gene or to inhibit pc5 activity for reducing restenosis occuring at injured vascular site |
| 04/30/2002 | US6380169 Metal complex containing oligonucleoside cleavage compounds and therapies |
| 04/30/2002 | US6380164 Modulating a cytokine mediated hepatic injury response in a mammal comprising administering a deltorphin (heptapeptide) selected from deltorphin i, deltorphin ii, and combinations thereof to mammal |
| 04/30/2002 | US6380163 Containing osmotic agent with an additional osmotic agent such as dextrose |
| 04/30/2002 | US6380162 Ice inhibiting peptides |
| 04/30/2002 | US6380161 Therapy of cancer, wherein a cancer chemotherapy agent is selected, conjugated to peptide, and one dose is administered to patient in therapeutically effective amount, and wherein peptide binds to a receptor for thrombospondin |